Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

29.70 +1.37 (+4.84%)

Streaming Delayed Price Updated: 9:39 AM EDT, Aug 25, 2026 Add to My Watchlist

Price and Volume

Volume	103,838
Open	28.92
Bid (Size)	29.44 (100)
Ask (Size)	29.70 (400)
Prev. Close	28.33
Today's Range	28.78 - 29.73
52wk Range	16.02 - 38.26
Shares Outstanding	79,199,501
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

August 04, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

July 23, 2026

Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET

From Beam Therapeutics

Via GlobeNewswire

Performance

YTD	+9.4%	+9.4%
1 Month	+18.5%	+18.5%
3 Month	-0.3%	-0.3%
6 Month	+4.8%	+4.8%
1 Year	+80.7%	+80.7%

More News

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗

July 20, 2026

Via The Motley Fool

BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗

January 12, 2026

Via Stocktwits

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗

July 08, 2026

Via The Motley Fool

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

June 18, 2026

From Beam Therapeutics

Via GlobeNewswire

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗

May 25, 2026

Via The Motley Fool

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances ↗

May 20, 2026

Via MarketBeat

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

May 18, 2026

From Beam Therapeutics

Via GlobeNewswire

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗

May 18, 2026

Via The Motley Fool

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

May 13, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

May 12, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

May 07, 2026

From Beam Therapeutics

Via GlobeNewswire

3 Biotech Stocks That Could Benefit from the Patent Cliff ↗

April 27, 2026

Via MarketBeat

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. ↗

April 11, 2026

Via The Motley Fool

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

Via MarketMinute

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

April 01, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

March 25, 2026

From Beam Therapeutics

Via GlobeNewswire

What's Going On With Beam Therapeutics Stock? ↗

February 24, 2026

Via Benzinga

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

February 24, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

February 24, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

February 23, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 ↗

February 01, 2026

Via The Motley Fool

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗

January 29, 2026

Via Stocktwits

Top stock movements in today's session. ↗

January 12, 2026

Via Chartmill

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?

Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Beam Therapeutics Inc. - Common Stock trade on?

Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?

The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market

What is the current price of Beam Therapeutics Inc. - Common Stock?

The current price of Beam Therapeutics Inc. - Common Stock is 29.70

When was Beam Therapeutics Inc. - Common Stock last traded?

The last trade of Beam Therapeutics Inc. - Common Stock was at 08/25/26 09:39 AM ET

What is the market capitalization of Beam Therapeutics Inc. - Common Stock?

The market capitalization of Beam Therapeutics Inc. - Common Stock is 2.35B

How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?

Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.